
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences reported a positive financial outlook with its liver disease franchise achieving $3 billion in FY24 sales, representing a 9% year-over-year increase, bolstered by the successful launch of Livdelzi. The HIV segment demonstrated robust performance, with sales rising 16% year-over-year to $19.6 billion in FY24, primarily driven by strong demand and favorable market conditions, alongside Descovy's impressive 21% year-over-year growth, exceeding consensus expectations. Additionally, Gilead's oncology portfolio, while facing competitive pressures, still managed a 12% year-over-year growth, reflecting the company's strategic expansions and resilience across its various therapeutic areas.
Bears say
The analysis indicates a negative outlook for Gilead Sciences's stock primarily due to anticipated revenue declines across several key product lines, including Veklury and HIV therapies. Expectations of flat year-over-year revenue and mid-teen percentage declines quarter-over-quarter for FY25, particularly in HIV revenue, contribute to concerns about growth sustainability. Additionally, competitive pressures from new entrants in both the hepatitis B and C markets and challenges in expanding the CAR-T treatment portfolio further exacerbate the potential for underperformance in Gilead’s financial metrics.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares